Alnylam Pharmaceuticals, Inc.

Based on a comprehensive analysis of ALNY, the investment case presents a high-risk, speculative profile that leans bearish in the near term. The stock is technically weak and fundamentally carries significant concerns that currently outweigh its potential.

Technical Analysis: ALNY is in a pronounced downtrend with severe recent underperformance against the market. While the declaration of potential oversold conditions must be weighed against the powerful downward momentum and substantial -37.2% drawdown, indicating clear negative sentiment.

Fundamentals & Valuation: While the company maintains strong revenue and a healthy gross margin, its profitability is declining, and its financial health is concerning due to high leverage and a negative interest coverage ratio. Most critically, ALNY appears significantly overvalued with extreme P/E and EV/EBITDA multiples that are not currently supported by its earnings growth, making its price difficult to justify.

Risk Assessment: The low beta is misleading, as the stock carries high idiosyncratic risk related to its biotech operations and financial structure. The primary appeal rests on long-term pipeline success, but near-term financial and valuation headwinds are substantial.

*Buy Recommendation: Based on this analysis, ALNY is not a recommended buy at this time. The combination of negative technical momentum, concerning leverage, and excessively high valuation creates substantial downside risk. Investors should wait for clear evidence of improving fundamentals, such as sustained profitability and debt reduction, or a more compelling valuation entry point before considering a position. This is not investment advice, for reference only.*

RockFlow Model Forecast: Three Scenarios for 2026

Based on a 12-month outlook, ALNY's trajectory is heavily dependent on pipeline catalysts overshadowed by significant near-term financial and valuation risks. The primary key catalyst is positive clinical or regulatory news from its RNAi therapeutic pipeline, which could reverse the negative sentiment; however, no major near-term milestones are assured. The most substantial potential risks are the combination of its high financial leverage, lack of profitability, and extreme valuation multiples, which leave the stock vulnerable to further declines if execution falters or market sentiment sours on speculative biotech. Given the absence of a consensus analyst target price and the current bearish technical and fundamental picture, a target price range is not prudent to establish; investors should await a fundamental improvement, such as sustained earnings or reduced debt, before considering an entry.

Wall Street Consensus

Most Wall Street analysts are optimistic about Alnylam Pharmaceuticals, Inc.'s 12-month outlook, with consensus target around $314.40, indicating expected upside potential.

Overall, ALNY has investment potential but also faces challenges. Here are key factors to weigh before investing.

ALNY has experienced significant underperformance with a substantial decline across multiple timeframes. The stock has trended sharply downward with notable volatility, particularly over the past quarter.

The stock's short-term performance is weak, with a -14.3% drop over one month accelerating to a -28.82% loss over three months. ALNY has severely underperformed the broader market by approximately 29% during this period, indicating significant stock-specific challenges impacting its price.

Currently trading at $314.4, ALNY sits in the lower half of its 52-week range ($205.87-$495.55), suggesting potential oversold conditions after its steep decline. While not at its absolute lows, the substantial -37.2% maximum drawdown highlights the pronounced selling pressure the stock has faced.

Revenue & Profitability ALNY maintains strong revenue generation with a solid gross profit margin of 76.0% in Q4 2025, indicating effective cost control on product costs. However, profitability metrics weakened from Q3 to Q4, with the operating income ratio declining from 29.5% to 12.0%, primarily due to increased operating expenses relative to revenue. The net income ratio of 17.0% remains healthy but shows quarter-to-quarter volatility in bottom-line performance.

Financial Health The company demonstrates adequate liquidity with a current ratio of 2.76 and quick ratio of 2.71, though the debt-equity ratio of 3.76 indicates significant leverage. The negative interest coverage ratio of -2.01 raises concerns about earnings ability to service debt obligations, while the cash flow to debt ratio of 0.06 suggests limited operating cash flow relative to total debt burden.

Operational Efficiency ALNY shows strong returns with an ROE of 23.6%, indicating effective use of shareholder equity, but asset efficiency appears constrained with a low asset turnover of 0.22. The operating cycle of 92 days and cash conversion cycle of 53 days reflect moderate working capital management, while the high company equity multiplier of 6.29 confirms substantial financial leverage driving ROE performance.

Based on the provided metrics, ALNY appears significantly overvalued by traditional measures. The trailing P/E ratio of 149.93 and forward P/E of approximately 70.5 are extremely high, indicating investors are paying a substantial premium for its current and anticipated earnings. This negative assessment is further supported by a deeply negative PEG ratio, which suggests a lack of earnings growth to justify the high multiple, and an exceptionally high EV/EBITDA of over 371, signifying weak operational profitability relative to its enterprise value.

A peer comparison cannot be accurately conducted as industry average data is unavailable. Without benchmarks for the biotechnology or pharmaceutical sector, it is impossible to determine if ALNY's elevated multiples are typical for high-growth, pre-profitability companies in its field or an outlier. This analysis therefore relies solely on the absolute levels of the valuation metrics, which, in isolation, paint a picture of a highly speculative and richly priced stock.

Volatility Risk: ALNY exhibits exceptionally low volatility risk relative to the broader market, as indicated by its Beta of 0.351. However, investors should be aware of substantial price depreciation risk, evidenced by a steep maximum one-year drawdown of -37.2%.

Other Risks: While the absence of reported short interest suggests a general lack of negative speculative pressure, this condition can sometimes mask complacency. Liquidity and operational execution risks specific to its biotech pipeline remain the primary non-volatility related concerns for the stock.